Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
674 stopped studies mapped to Digestive System Adenocarcinoma and descendants · 93% state a reason
Over the 674 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02366819 | Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating… | Phase 4 | suspended | Feb 19, 2015 | University of Chicago | Pending data analysis | Other (stated, no rule matched) |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With… | Phase 1 | terminated | Jan 21, 2020 | SOTIO Biotech AG | Due to lack of efficacy shown at the time of the interim analysis. | Efficacy / futility |
| NCT06599502 | A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and…(ALAFOSS-01) | Phase 1 | terminated | Sep 19, 2024 | AstraZeneca | The decision to cease enrolment and proceed with the early termination of the ALAFOSS 01… | Enrollment / accrual |
| NCT02439008 | Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word… | N/A | terminated | May 8, 2015 | Centre Oscar Lambret | Lack of patient enrollment | Enrollment / accrual |
| NCT04777851 | Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7(REPLACE) | Phase 3 | terminated | Mar 2, 2021 | Translational Research in Oncology | The trial ended earlier than planned due to slow enrolment, which has made it unfeasible to achieve… | Enrollment / accrual |
| NCT04327700 | Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib | Phase 2 | terminated | Mar 31, 2020 | Wake Forest University Health Sciences | Slow accruals | Enrollment / accrual |
| NCT06287463 | Study of DCC-3084 in Participants With Advanced Malignancies Driven by the… | Phase 1 | terminated | Mar 1, 2024 | Deciphera Pharmaceuticals, LLC | Trial terminated due to a business decision, not based on any safety concerns. | Safety / toxicity |
| NCT06625515 | First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or… | Phase 1 | terminated | Oct 3, 2024 | Accent Therapeutics | The study was terminated by sponsor based on the adverse event profile. | Safety / toxicity |
| NCT03785210 | Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary… | Phase 2 | terminated | Dec 24, 2018 | National Cancer Institute (NCI) | Study was terminated due to poor accrual. | Enrollment / accrual |
| NCT06217094 | Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing… | Phase 1 | withdrawn | Jan 22, 2024 | University of Florida | funding terminated | Funding |
| NCT06851104 | A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With… | Phase 2 | terminated | Feb 28, 2025 | Guangxi Medical University | The support from the relevant company was not obtained as planned | Sponsor / business decision |
| NCT05489250 | The PLATON Network(PLATON) | — | terminated | Aug 5, 2022 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Sponsor Decision | Sponsor / business decision |
| NCT04258566 | Electromagnetic Tracking and Optical Imaging With ICG for Hepatic Biopsies | N/A | terminated | Feb 6, 2020 | National Institutes of Health Clinical Center (CC) | Recruitment difficulty | Enrollment / accrual |
| NCT06560645 | A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic… | Phase 1 | terminated | Aug 19, 2024 | Prelude Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT06290856 | Clinical Utility of Selected Circulating Tumor DNA Assays in Patients With Advanced… | — | terminated | Mar 4, 2024 | Oslo University Hospital | The platform used for detecting ctDNA was not sensitive enough. | Other (stated, no rule matched) |
| NCT05070247 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced… | Phase 1 / Phase 2 | terminated | Oct 7, 2021 | Takeda | Clinical Futility of TAK 500 met. No further development with this compound | Efficacy / futility |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally… | Phase 1 / Phase 2 | terminated | Feb 7, 2020 | Ocellaris Pharma, Inc. | Business Decision | Sponsor / business decision |
| NCT02917759 | Liver and Biliary Tumor Tissue Registry | — | terminated | Sep 28, 2016 | Mayo Clinic | Lack of funding to support enrollment | Enrollment / accrual |
| NCT06478862 | Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations… | Phase 2 | terminated | Jun 27, 2024 | Lipomedix Pharmaceuticals Inc. | Sponsor decision | Sponsor / business decision |
| NCT04805788 | Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer | Phase 2 | terminated | Mar 18, 2021 | Mayo Clinic | slow accrual | Enrollment / accrual |
| NCT07283848 | Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma | Phase 2 | withdrawn | Dec 16, 2025 | Massachusetts General Hospital | The pharmaceutical company is not moving forward with this intervention due to lack of efficacy. | Efficacy / futility |
| NCT05977322 | A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. | Phase 1 | terminated | Aug 4, 2023 | Novartis Pharmaceuticals | The decision was not based on any safety concerns | Safety / toxicity |
| NCT06626256 | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable… | Phase 1 | withdrawn | Oct 3, 2024 | City of Hope Medical Center | no resource | Other (stated, no rule matched) |
| NCT03042169 | Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage…(SURGIGAST) | Phase 3 | terminated | Feb 3, 2017 | University Hospital, Lille | default inclusion | Other (stated, no rule matched) |
| NCT05044676 | Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for…(IMMUNOCELL) | — | terminated | Sep 16, 2021 | Assistance Publique - Hôpitaux de Paris | Abandon of study | Other (stated, no rule matched) |
| NCT05171166 | Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized… | Phase 2 / Phase 3 | terminated | Dec 28, 2021 | Peking University | Difficult to enroll participants | Enrollment / accrual |
| NCT05289830 | Escitalopram to Placebo in Patients With Localized Pancreatic Cancer | Phase 2 | terminated | Mar 21, 2022 | Case Comprehensive Cancer Center | Slow accrual | Enrollment / accrual |
| NCT04779151 | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and…(NIRADO) | Phase 2 | terminated | Mar 3, 2021 | Gustave Roussy, Cancer Campus, Grand Paris | Abandon of the partner, GSK | Other (stated, no rule matched) |
| NCT05252416 | (VELA) Study of BLU-222 in Advanced Solid Tumors | Phase 1 | terminated | Feb 23, 2022 | Blueprint Medicines Corporation | This trial was terminated prior to the initiation of Phase 2 for reasons not due to safety concerns. | Safety / toxicity |
| NCT06320080 | Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of… | Phase 1 | terminated | Mar 20, 2024 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | This study was closed due to business reasons. Closure was not prompted by any safety or efficacy… | Safety / toxicity |
| NCT05417386 | FOLFIRINOX + NIS793 in Pancreatic Cancer | Phase 1 | terminated | Jun 14, 2022 | Colin D. Weekes, M.D., PhD | NIS793 is no longer being developed | Other (stated, no rule matched) |
| NCT06994299 | A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab…(PRISM) | Phase 2 | withdrawn | May 29, 2025 | Weill Medical College of Cornell University | Drug and financial support not available for the study. | Funding |
| NCT05256381 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety… | Phase 2 | terminated | Feb 25, 2022 | SOTIO Biotech AG | Due to lack of expected efficacy shown at the time of the interim analysis | Efficacy / futility |
| NCT02881554 | Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or… | N/A | terminated | Aug 29, 2016 | University of Washington | Terminated due to low accrual in Cohort B. (Accrual goal for Cohort A was met.) | Enrollment / accrual |
| NCT05033522 | Immunotherapy for Advanced Liver Cancer(ALIVE) | Phase 2 / Phase 3 | suspended | Sep 2, 2021 | Mirror Biologics, Inc. | Sponsor unable to fund | Funding |
| NCT05220722 | Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors | Phase 1 / Phase 2 | terminated | Feb 2, 2022 | TriSalus Life Sciences, Inc. | The decision was made to terminate the study after the completion of Phase 1b enrollment and not… | Safety / toxicity |
| NCT05229601 | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | Feb 8, 2022 | HiFiBiO Therapeutics | The decision to discontinue the trial was made as part of a strategic review of the Sponsor's… | Safety / toxicity |
| NCT03144661 | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced… | Phase 1 | terminated | May 9, 2017 | Incyte Corporation | Strategic Business Decision | Sponsor / business decision |
| NCT04050462 | Nivolumab Combined With BMS-986253 in HCC Patients | Phase 2 | terminated | Aug 8, 2019 | NYU Langone Health | Study was terminated early by the drug sponsor due to slow accrual and a change in the company's… | Enrollment / accrual |
| NCT04712721 | Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3… | Early Phase 1 | terminated | Jan 15, 2021 | Novartis Pharmaceuticals | Business reasons | Sponsor / business decision |
| NCT04363801 | A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With…(DisTinGuish) | Phase 2 | terminated | Apr 27, 2020 | Leap Therapeutics, Inc. | experimental treatment will not be more efficacious than its comparator in the primary endpoint of… | Other (stated, no rule matched) |
| NCT06302400 | Individualized Dosimetry for Holmium-166 Radioembolization in Patients With Unresectable…(RHEPaiR) | N/A | terminated | Mar 8, 2024 | Imperial College London | Terumo Europe NV permanently discontinued production of Holmium platform SIRT product range | Other (stated, no rule matched) |
| NCT05582018 | Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of…(PANORAMA) | N/A | terminated | Oct 17, 2022 | Techsomed Medical Technologies LTD | Sponsor decision | Sponsor / business decision |
| NCT05678257 | A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer | Phase 2 | terminated | Jan 10, 2023 | NuCana plc | A pre-planned initial analysis concluded that the study was unlikely to achieve its primary… | Other (stated, no rule matched) |
| NCT06690281 | A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H… | Phase 2 | withdrawn | Nov 15, 2024 | National Cancer Institute (NCI) | PI left NIH. | Investigator |
| NCT04502082 | Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1) | Phase 1 | terminated | Aug 6, 2020 | Eureka Therapeutics Inc. | The trial was intended to be a Phase 1/2 trial, but the sponsor terminated the trial prior to… | Other (stated, no rule matched) |
| NCT03765736 | Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal… | — | terminated | Dec 5, 2018 | Academic and Community Cancer Research United | Low accrual | Enrollment / accrual |
| NCT05009979 | 18F-DCFPyL PET/CT in Hepatocellular Carcinoma | Phase 2 | terminated | Aug 18, 2021 | National Cancer Institute (NCI) | Reason for termination was a combination of slow accrual in setting of austerity measures regarding… | Enrollment / accrual |
| NCT05451862 | Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular…(HOMIE-166) | N/A | terminated | Jul 11, 2022 | Terumo Europe N.V. | The HOMIE-166 clinical investigation was prematurely terminated due to sponsor's decision to… | Sponsor / business decision |
| NCT05605522 | A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours | Phase 1 | terminated | Nov 4, 2022 | 3B Pharmaceuticals GmbH | Sponsor reprioritization of active trials. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Mar 30, 2026source: clinicaltrials